PFE Related Major News
-
Pfizer, Inc. (PFE) Misses Q1 EPS by 1c; Updates FY13 Outlook
-
Pfizer's Zoeti (ZTS) IPO Prices at $26, Above Expected Range
-
Pfizer (PFE) Delivers Q4 Beat but 2013 EPS a Tad Light
-
Pfizer, Inc. (PFE) Tops Q4 EPS by 3c; Guides In-Line
-
Pfizer, Inc. (PFE) Reports In-Line Q3 EPS; Announces $10B Buyback Plan
-
Pfizer (PFE) Trims FY12 adj.-EPS Outlook on AstraZeneca (AZN) NEXIUM Deal
-
Pfizer's (PFE) Zoetis Unit Files for IPO; Will Transfer Over Animal Health Segment
-
Pfizer (PFE) Beats Q2 on Top and Bottom Line; Looks to IPO 20% of Animal Health Unit
-
Pfizer, Inc. (PFE) Tops Q2 EPS by 8c; Reaffirms Outlook; to File IPO for Animal Health Unit
-
Loss of Lipitor Leaves Pfizer (PFE) Limping Following Q1 Numbers; Cuts FY12 Outlook
-
Pfizer, Inc. (PFE) Tops Q1 EPS by 2c; Cuts FY12 Outlook
-
Pfizer (PFE) Will Sell Nutrition Business to Nestle in $11.85B Cash Deal
-
Pfizer (PFE) Q4 Results Look Strong But FY12 Guidance Lowered
-
Pfizer (PFE) Reduces FY12 EPS Outlook
-
Pfizer, Inc. (PFE) Tops Q4 EPS by 3c; Cuts FY12 Outlook
-
Pfizer (PFE) Tops the Street in Q3, Raises FY11 Outlook; Still Well-Positioned for Lipitor Expiration
-
Pfizer, Inc. (PFE) Tops Q3 EPS by 7c; Raises Buyback Target to $7-$9B; Reaffirms Outlook
-
Pfizer (PFE) Q2 Results Reflect Exclusivity Losses; Reaffirms Guidance
-
Pfizer, Inc. (PFE) Tops Q2 EPS by 1c; Affirms Outlook
-
Pfizer (PFE) Exploring Options for Animal Health And Nutrition Businesses
-
Pfizer Inc. (PFE) Tops Q1 EPS by 1c; Reaffirms Outlook
-
Pfizer (PFE) Cuts FY11, FY12 Sales Outlook
-
Pfizer (PFE) Tops Street in Q4; Announced $5B Buyback, Mixed Guidance
-
Pfizer (PFE) Tops Q4 EPS by 1c; Reports $5B Buyback; Guides FY11, Raises FY12 Outlook
-
Ian Read Elected Pres/CEO of Pfizer (PFE)
-
Pfizer (PFE) Q3 Profit Falls 70% on Charges; Guides FY10
-
Pfizer (PFE) Posts Q3 Adj-EPS of $0.54, Tops by 3c; Lowers Top-End of FY10 Revs Outlook, Increases EPS Guidance
-
Pfizer (PFE) Surprises Wall Street with Strong Q2 'Beat'; "Impressive" Proclaim Analysts
-
Pfizer (PFE) Tops Q1 Views and Reaffirms Outlook
-
Pfizer (PFE) Posts Q1 EPS of $0.60, Beats by 7c; Reaffirms Outlook
-
Pfizer (PFE) Slightly Misses Q4 Profit Expectations and Gives 2012 Forecast, Shares Slump
-
Pfizer (PFE) Posts Q4 EPS of $0.49, Misses by 1c; Guides FY10 EPS Below Street
-
Pfizer (PFE) Tops Q3 EPS by 3c; Guides Higher
-
Pfizer (PFE) Tops Q2 EPS by 1c; Guides
-
Pfizer (PFE) Tops Q1 EPS by 5c; Reaffirms
-
Pfizer (PFE) Reports Q4 Results, Guides Below The Street; Cutting 10% of Workforce
-
Reports Pfizer (PFE) In Talks To Acquire Wyeth (WYE)
-
Pfizer (PFE) Reports Q3 Adj-EPS of $0.62, Beats by 2c; Narrows FY09 Outlook
-
Bristol-Myers (BMY) and Pfizer (PFE) Provide Update on Apixaban Clinical Development Program - Primary Endpoint Not Met
-
Pfizer (PFE) Tops Q2 EPS by 1c; Guides
-
Pfizer (PFE) Misses Q1 EPS by 5c; Reaffirms Guidance
-
Pfizer (PFE) Tops Q4 Views; Boosts Guidance
Back to PFE Stock Lookup
